Ezra Cohen to Tumor Microenvironment
This is a "connection" page, showing publications Ezra Cohen has written about Tumor Microenvironment.
Connection Strength
0.647
-
Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer. Nat Cancer. 2026 Jan; 7(1):98-115.
Score: 0.167
-
The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification. Clin Cancer Res. 2021 02 01; 27(3):689-703.
Score: 0.117
-
Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. Clin Cancer Res. 2019 07 15; 25(14):4211-4223.
Score: 0.104
-
Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight. 2017 09 21; 2(18).
Score: 0.094
-
Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial. JAMA Oncol. 2024 01 01; 10(1):32-41.
Score: 0.036
-
Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma. J Cancer Res Clin Oncol. 2023 Nov; 149(15):14125-14136.
Score: 0.035
-
Somatic 9p24.1 alterations in HPV- head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity. Proc Natl Acad Sci U S A. 2022 11 22; 119(47):e2213835119.
Score: 0.034
-
Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients. Clin Cancer Res. 2021 11 15; 27(22):6075-6082.
Score: 0.031
-
Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. Nat Commun. 2021 04 22; 12(1):2383.
Score: 0.030